Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Fate Therapeutics Inc.’s qualification as a “smaller reporting company” and a “non-accelerated filer” presents a substantial business risk. By opting to adhere to the lenient reporting requirements afforded to such entities, the company may alienate investors seeking the more comprehensive disclosure typical of larger, accelerated filers. This decision could lead to reduced investor interest, a decrease in trading volume, and potentially heightened volatility in the market price of Fate Therapeutics’ common shares, amplifying the investment risk profile.
The average FATE stock price target is $6.45, implying 58.09% upside potential.
To learn more about Fate Therapeutics Inc’s risk factors, click here.
